How Karyopharm Therapeutics KPTI pricing changes flow through to earnings KPTI Q4 2025 Earnings Karyopharm Therapeutics Misses Forecast as Loss Widens ATI Inc ATI tops Q4 2025 EPS forecasts and posts 52 percent annual revenue growth but shares drop 38 percent today The balance sheet strength behind Phoenix FENG results HAFN Hafnia shares rise 14 despite earnings miss revenue slides 20 yearoveryear What Deere DE bond yields suggest about risk DE Deere Q1 2026 Earnings EPS Surges 15 on Strong Farming Demand Does Driven Brands DRVN stock carry significant risk Builds on Momentum 20260418 Johnson Johnson JNJ Dividend Aristocrat Extends 64Year Payout Growth Streak with Robust Coverage